arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

BridgeBio Pharma, Inc.

BBIO
$74.28 ▼ -3.69 (-4.73%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
52
Health
Fair
Neutral
auto_awesome

Analytical Summary

BridgeBio Pharma, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $14.6B
Dividend Yield —
Revenue Growth 192.6% ↗
Op. Margin -3.3% ↗
ROIC -1.2% ↗
FCF / Share $-0.23 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -1.58
info Valuation on last close. End-of-day price, Nov 5, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$353.17M
↑ +192.6% —
Net Income Profit after all expenses
$-56.71M
↑ +69.3% —
Operating Margin Operating profit as % of sales
-3.3%
↑ +92.5% 2th
FCF / Share Free cash flow per share
$-0.23
↑ +37.9% —
Long-Term Debt Long-term obligations
$2.63B
↓ -0.9% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
2
Returns ↓
94
Financial Health ↓
64
Cash Quality ↓
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 36 quarters